BioSpace News Archive

Aquestive Therapeutics, Inc., a specialty pharmaceutical company focused on identifying, developing and commercializing differentiated products to address unmet medical needs, today announced the underwriters of its previously announced initial public offering of common stock have partially exercised their over-allotment option to purchase additional shares.

Medpace Holdings, Inc. announced that it will present at the following investor conference in September:

DATATRAK International, Inc. announces an $8,000,000 additional commitment from its long-term investor TabaFund (Tabatabai Investment Partners LP) to expand the company’s growth in sales and new technologies for the life sciences and clinical research industry.

MiMedx Group, Inc. announced that it received written notification, as expected, from the Nasdaq Stock Market indicating that the Company’s failure to timely file a Form 10-Q for the period ended June 30, 2018 could serve as an additional basis for delisting

On August 14, 2018, Navidea Biopharmaceuticals, Inc. received a letter from NYSE American LLC (“NYSE American” or the “Exchange”) stating that it is not in compliance with the continued listing standards

Promising new platform can rapidly respond to emerging infectious diseases

Telix Pharmaceuticals Limited and Nihon Medi-Physics Co., Ltd. have today announced that they have entered into a memorandum of understanding (MOU) for a commercial partnership in renal cancer imaging for the Japanese market.

Bernstein Liebhard LLP is investigating potential securities fraud claims on behalf of shareholders of Rockwell Medical, Inc.

Addus HomeCare Corporation announced the pricing of an underwritten public offering of 2,100,000 shares of common stock (“Common Stock”) at the public offering price of $59.00 per share.

American Specialty Health Ranks No. 3833 on the 2018 Inc. 5000 List With Three-Year Revenue Growth of 94%